Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

医学 帕妥珠单抗 乳腺癌 曲妥珠单抗 多西紫杉醇 内科学 肿瘤科 来曲唑 三苯氧胺 卡铂 化疗 随机对照试验 临床终点 癌症 顺铂
作者
José Manuel Pérez-García,Géraldine Gebhart,Manuel Ruíz Borrego,Agostina Stradella,Begoña Bermejo,Peter Schmid,Frederik Marmé,Santiago Escrivá-de-Romaní,Lourdes Calvo,Nuria Ribelles,Noelia Martínez-Jáñez,Cinta Albacar,Aleix Prat,Florence Dalenc,Khaldoun Kerrou,Marco Colleoni,N. Afonso,Serena Di Cosimo,Miguel Sampayo-Cordero,Andrea Malfettone
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (6): 858-871 被引量:117
标识
DOI:10.1016/s1470-2045(21)00122-4
摘要

Several de-escalation approaches are under investigation in patients with HER2-positive, early-stage breast cancer. We assessed early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose (18F-FDG)-PET (18F-FDG-PET) and the possibility of chemotherapy de-escalation using a pathological response-adapted strategy.We did a multicentre, randomised, open-label, non-comparative, phase 2 trial in 45 hospitals in Spain, France, Belgium, Germany, the UK, Italy, and Portugal. Eligible participants were women aged 18 years or older with centrally confirmed, HER2-positive, stage I-IIIA, invasive, operable breast cancer (≥1·5 cm tumour size) with at least one breast lesion evaluable by 18F-FDG-PET, an Eastern Cooperative Oncology Group performance status of 0 or 1, and a baseline left ventricular ejection fraction of at least 55%. We randomly assigned participants (1:4), via an interactive response system using central block randomisation with block sizes of five, stratified by hormone receptor status, to either docetaxel (75 mg/m2 intravenous), carboplatin (area under the concentration-time curve 6 mg/mL per min intravenous), trastuzumab (subcutaneous 600 mg fixed dose), and pertuzumab (intravenous 840 mg loading dose, 420 mg maintenance doses; group A); or trastuzumab and pertuzumab (group B). Hormone receptor-positive patients allocated to group B were additionally given letrozole if postmenopausal (2·5 mg/day orally) or tamoxifen if premenopausal (20 mg/day orally). Centrally reviewed 18F-FDG-PET scans were done before randomisation and after two treatment cycles. Patients assigned to group A completed six cycles of treatment (every 3 weeks) regardless of 18F-FDG-PET results. All patients assigned to group B initially received two cycles of trastuzumab and pertuzumab. 18F-FDG-PET responders in group B continued this treatment for six further cycles; 18F-FDG-PET non-responders in this group were switched to six cycles of docetaxel, carboplatin, trastuzumab, and pertuzumab. Surgery was done 2-6 weeks after the last dose of study treatment. Adjuvant treatment was selected according to the neoadjuvant treatment administered, pathological response, hormone receptor status, and clinical stage at diagnosis. The coprimary endpoints were the proportion of 18F-FDG-PET responders in group B with a pathological complete response in the breast and axilla (ypT0/is ypN0) as determined by a local pathologist after surgery after eight cycles of treatment, and 3-year invasive disease-free survival of patients in group B, both assessed by intention to treat. The definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these data are not included in this Article. Safety was assessed in all participants who received at least one dose of study drug. Health-related quality-of-life was assessed with EORTC QLQ-C30 and QLQ-BR23 questionnaires at baseline, after two cycles of treatment, and before surgery. This trial is registered with EudraCT (2016-002676-27) and ClinicalTrials.gov (NCT03161353), and is ongoing.Between June 26, 2017, and April 24, 2019, we randomly assigned 71 patients to group A and 285 to group B. Median follow-up was 5·7 months (IQR 5·3-6·0). 227 (80%) of 285 patients in group B were 18F-FDG-PET responders, of whom 86 (37·9%, 95% CI 31·6-44·5; p<0·0001 compared with the historical rate) of 227 had a pathological complete response. The most common haematological grade 3-4 adverse events were anaemia (six [9%] of 68 patients in group A vs four [1%] of 283 patients in group B), neutropenia (16 [24%] vs ten [4%]), and febrile neutropenia (14 [21%] vs 11 [4%]). Serious adverse events occurred in 20 (29%) of 68 patients in group A versus 13 (5%) of 283 patients in group B. No deaths were reported during neoadjuvant treatment. Global health status declined by at least 10% in 65·0% (95% CI 46·5-72·4) and 35·5% (29·7-41·7) of patients in groups A and B, respectively INTERPRETATION: 18F-FDG-PET identified patients with HER2-positive, early-stage breast cancer who were likely to benefit from chemotherapy-free dual HER2 blockade with trastuzumab and pertuzumab, and a reduced impact on global health status. Depending on the forthcoming results for the 3-year invasive disease-free survival endpoint, this strategy might be a valid approach to select patients not requiring chemotherapy.F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
去为我我完成签到,获得积分10
2秒前
2秒前
鬲木发布了新的文献求助10
2秒前
3秒前
siren完成签到,获得积分10
4秒前
本是个江湖散人完成签到,获得积分10
7秒前
思源应助鬲木采纳,获得10
7秒前
无情平松完成签到,获得积分10
8秒前
8秒前
脑洞疼应助草上飞采纳,获得10
8秒前
小鸣完成签到 ,获得积分10
9秒前
陈苗发布了新的文献求助10
9秒前
cx完成签到 ,获得积分10
10秒前
xinxinbaby发布了新的文献求助10
11秒前
dandna完成签到 ,获得积分10
12秒前
去为我我发布了新的文献求助10
12秒前
12秒前
明明发布了新的文献求助10
12秒前
15秒前
15秒前
奥特超曼应助十七采纳,获得10
16秒前
16秒前
17秒前
活力鸡完成签到,获得积分10
17秒前
NexusExplorer应助yang采纳,获得10
18秒前
18秒前
英姑应助泥嚎采纳,获得10
18秒前
夜猫酱酱子完成签到,获得积分10
18秒前
imkhun1021发布了新的文献求助10
20秒前
mingming发布了新的文献求助10
21秒前
22秒前
黎雪芳完成签到,获得积分10
22秒前
23秒前
imkhun1021完成签到,获得积分10
25秒前
25秒前
26秒前
26秒前
张雯思发布了新的文献求助10
26秒前
爆米花应助小明采纳,获得10
26秒前
我很厉害的完成签到,获得积分10
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989660
求助须知:如何正确求助?哪些是违规求助? 3531826
关于积分的说明 11255082
捐赠科研通 3270447
什么是DOI,文献DOI怎么找? 1804981
邀请新用户注册赠送积分活动 882136
科研通“疑难数据库(出版商)”最低求助积分说明 809176